Compare Inovio Pharmaceuticals Inc (INO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while First Trust Cloud Computing ETF trades at $137.18. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SKYY | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $155.17 |
52-Week Low | $1.05 | $104.16 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
First Trust Cloud Computing ETF (SKYY) trades at $136.66, up 0.41% with a bullish technical signal from moving averages. The ETF provides diversified exposure to cloud computing companies amid strong sector inflows driven by enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs, with SKYY positioned as a core holding for cloud computing exposure.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include technology sector volatility and competitive pressures from alternative cloud ETFs. Analyst coverage emphasizes SKYY's established track record since 2011 launch and broad market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
